Search

Your search keyword '"Mattei, D"' showing total 384 results
Start Over Author "Mattei, D"
384 results on '"Mattei, D"'

1. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, and Martinelli G

Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax + HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60 days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax + HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax + HMA effectiveness and toxicities in real life.

Published
2023

3. Brain in flames – animal models of psychosis: utility and limitations

Author

Mattei D, Schweibold R, and Wolf SA

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Daniele Mattei,1 Regina Schweibold,1,2 Susanne A Wolf1 1Department of Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany; 2Department of Neurosurgery, Helios Clinics, Berlin, Germany Abstract: The neurodevelopmental hypothesis of schizophrenia posits that schizophrenia is a psychopathological condition resulting from aberrations in neurodevelopmental processes caused by a combination of environmental and genetic factors which proceed long before the onset of clinical symptoms. Many studies discuss an immunological component in the onset and progression of schizophrenia. We here review studies utilizing animal models of schizophrenia with manipulations of genetic, pharmacologic, and immunological origin. We focus on the immunological component to bridge the studies in terms of evaluation and treatment options of negative, positive, and cognitive symptoms. Throughout the review we link certain aspects of each model to the situation in human schizophrenic patients. In conclusion we suggest a combination of existing models to better represent the human situation. Moreover, we emphasize that animal models represent defined single or multiple symptoms or hallmarks of a given disease. Keywords: inflammation, schizophrenia, microglia, animal models

Published
2015

4. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Author

Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foa R, Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, and Foa R

Abstract

Early recognition of Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) cases could impact on the management and outcome of this subset of B-lineage ALL. In order to assess the prognostic value of the Ph-like status in a pediatric-inspired, minimal residual disease (MRD)driven trial, we screened 88 B-lineage ALL cases negative for major fusion genes (BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 and KTM2Ar) enrolled in the GIMEMA LAL1913 front-line protocol for adult BCR/ABL1-negative ALL. The screening - performed using the “BCR/ABL1-like predictor” - identified 28 Ph-like cases (31.8%), characterized by CRLF2 overexpression (35.7%), JAK/STAT pathway mutations (33.3%), IKZF1 (63.6%), BTG1 (50%) and EBF1 (27.3%) deletions, and rearrangements targeting tyrosine kinases or CRLF2 (40%). The correlation with outcome highlighted that: i) the complete remission rate was significantly lower in Ph-like compared to non-Ph-like cases (74.1% vs. 91.5%, P=0.044); ii) at time point 2, decisional for transplant allocation, 52.9% of Ph-like cases versus 20% of non-Ph-like were MRD-positive (P=0.025); iii) the Ph-like profile was the only parameter associated with a higher risk of being MRD-positive at time point 2 (P=0.014); iv) at 24 months, Ph-like patients had a significantly inferior event-free and disease-free survival compared to non-Ph-like patients (33.5% vs. 66.2%, P=0.005 and 45.5% vs. 72.3%, P=0.062, respectively). This study documents that Ph-like patients have a lower complete remission rate, event-free survival and disease-free survival, as well as a greater MRD persistence also in a pediatric-oriented and MRD-driven adult ALL protocol, thus reinforcing that the early recognition of Ph-like ALL patients at diagnosis is crucial to refine risk-stratification and to optimize therapeutic strategies.

Published
2021

5. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Author

Bassan, R., primary, Chiaretti, S., additional, Della Starza, I., additional, Spinelli, O., additional, Santoro, A., additional, Elia, L., additional, De Propris, M. S., additional, Scattolin, A. M., additional, Paoloni, F., additional, Messina, M., additional, Audisio, E., additional, Marbello, L., additional, Borlenghi, E., additional, Zappasodi, P., additional, Vetro, C., additional, Martinelli, G., additional, Mattei, D., additional, Fracchiolla, N., additional, Bocchia, M., additional, De Fabritiis, P., additional, Bonifacio, M., additional, Candoni, A., additional, Cassibba, V., additional, Di Bartolomeo, P., additional, Latte, G., additional, Trappolini, S., additional, Guarini, A., additional, Vitale, A., additional, Fazi, P., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

6. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

Author

Loges, S., primary, Heuser, M., additional, Chromik, J., additional, Sutamtewagul, G., additional, Kapp-Schwoerer, S., additional, Crugnola, M., additional, Di Renzo, N., additional, Lemoli, R., additional, Mattei, D., additional, Ben-Batalla, I., additional, Waizenegger, J., additional, Rieckmann, L.-M., additional, Janning, M., additional, Imbusch, C. D., additional, Beumer, N., additional, Micklem, D., additional, Gorcea-Carson, C., additional, Lawson, G., additional, Nautiyal, J., additional, Deharo, S., additional, Fiedler, W., additional, Alvarado-Valero, Y., additional, and Gjertsen, B., additional

Published
2022
Full Text
View/download PDF

7. Microplastics in drinking water: national working group and analytical methods

Author

Martellone, L., Brancaleone, E., Mattei, D., Fuscoletti, V., Lucentini, L., Favero, G., Gerardo, Califano, Anna Luisa Salvatore, Tania, Tellini, Giuseppe, Bortone, and Gruppo Nazionale di Lavoro, Microplastiche.

Subjects
emerging pollutants, microplastics, contaminanti emergenti, microplastiche, acqua potabile, drinking water
Published
2022

11. Reduction of cortical parvalbumin expressing GABAergic interneurons in a rodent hyperoxia model of preterm birth brain injury with deficits in social behavior and cognition

Author

Scheuer, T., Auf dem Brinke, E., Grosser, S., Wolf, S.A., Mattei, D., Sharkovska, Y., Barthel, P.C., Endesfelder, S., Friedrich, V., Bührer, C., Vida, I., and Schmitz, T.

Subjects
Function and Dysfunction of the Nervous System
Abstract

The inhibitory GABAergic system in the brain is involved in the etiology of various psychiatric problems, including autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and others. These disorders are influenced not only by genetic but also by environmental factors, such as preterm birth, although the mechanisms underlying are not known. In a translational hyperoxia model, exposing mice pups at age P5 to 80% oxygen for 48 hours to mimic a steep rise of oxygen exposure caused by preterm birth from in utero into room air, we documented a persistent reduction of cortical mature parvalbumin expressing interneurons until adulthood. Developmental delay of cortical myelin was observed together with decreased expression of oligodendroglial glial cell-derived neurotrophic factor (GDNF), a factor being involved in interneuronal development. Electrophysiological and morphological properties of remaining interneurons were unaffected. Behavioral deficits were observed for social interaction, learning, and attention. These results elucidate that neonatal oxidative stress can lead to decreased interneuron density and to psychiatric symptoms. The obtained cortical myelin deficit and decreased oligodendroglial GDNF expression indicate an impaired oligodendroglial-interneuronal interplay contributes to interneuronal damage.

Published
2021

14. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, Martinelli, G, Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, and Martinelli, G

Published
2021

15. Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

Author

Caprioli, C, Lussana, F, Salmoiraghi, S, Cavagna, R, Buklijas, K, Elidi, L, Zanghi', P, Michelato, A, Delaini, F, Oldani, E, Intermesoli, T, Grassi, A, Gianfaldoni, G, Mannelli, F, Ferrero, D, Audisio, E, Terruzzi, E, De Paoli, L, Cattaneo, C, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, A, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Falini, B, Pavoni, C, Bassan, R, Spinelli, O, Rambaldi, A, Caprioli, Chiara, Lussana, Federico, Salmoiraghi, Silvia, Cavagna, Roberta, Buklijas, Ksenija, Elidi, Lara, Zanghi', Pamela, Michelato, Anna, Delaini, Federica, Oldani, Elena, Intermesoli, Tamara, Grassi, Anna, Gianfaldoni, Giacomo, Mannelli, Francesco, Ferrero, Dario, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Cattaneo, Chiara, Borlenghi, Erika, Cavattoni, Irene, Tajana, Monica, Scattolin, Anna Maria, Mattei, Daniele, Corradini, Paolo, Campiotti, Leonardo, Ciceri, Fabio, Bernardi, Massimo, Todisco, Elisabetta, Cortelezzi, Agostino, Falini, Brunangelo, Pavoni, Chiara, Bassan, Renato, Spinelli, Orietta, Rambaldi, Alessandro, Caprioli, C, Lussana, F, Salmoiraghi, S, Cavagna, R, Buklijas, K, Elidi, L, Zanghi', P, Michelato, A, Delaini, F, Oldani, E, Intermesoli, T, Grassi, A, Gianfaldoni, G, Mannelli, F, Ferrero, D, Audisio, E, Terruzzi, E, De Paoli, L, Cattaneo, C, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, A, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Falini, B, Pavoni, C, Bassan, R, Spinelli, O, Rambaldi, A, Caprioli, Chiara, Lussana, Federico, Salmoiraghi, Silvia, Cavagna, Roberta, Buklijas, Ksenija, Elidi, Lara, Zanghi', Pamela, Michelato, Anna, Delaini, Federica, Oldani, Elena, Intermesoli, Tamara, Grassi, Anna, Gianfaldoni, Giacomo, Mannelli, Francesco, Ferrero, Dario, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Cattaneo, Chiara, Borlenghi, Erika, Cavattoni, Irene, Tajana, Monica, Scattolin, Anna Maria, Mattei, Daniele, Corradini, Paolo, Campiotti, Leonardo, Ciceri, Fabio, Bernardi, Massimo, Todisco, Elisabetta, Cortelezzi, Agostino, Falini, Brunangelo, Pavoni, Chiara, Bassan, Renato, Spinelli, Orietta, and Rambaldi, Alessandro

Abstract

Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these features, uncertainties remain to identify the secondary nature of some cases otherwise defined as de novo AML. To test whether a chromatin-spliceosome (CS) mutational signature might better inform the definition of the de novo AML group, we analyzed a prospective cohort of 413 newly diagnosed AML patients enrolled into a randomized clinical trial (NILG AML 02/06) and provided with accurate cytogenetic and molecular characterization. Among clinically defined de novo AML, 17.6% carried CS mutations (CS-AML) and showed clinical characteristics closer to sAML (older age, lower white blood cell counts and higher rate of multilineage dysplasia). Outcomes in this group were adverse, more similar to those of sAML as compared to de novo AML (overall survival, 30% in CS-AML and 17% in sAML vs 61% in de novo AML, P<0.0001; disease free survival, 26% in CS-AML and 22% in sAML vs 54% of de novo AML, P<0.001) and independently confirmed by multivariable analysis. Allogeneic transplant in first complete remission improved survival in both sAML and CS-AML patients. In conclusion, these findings highlight the clinical significance of identifying CS-AML for improved prognostic prediction and potential therapeutic implications. (NILG AML 02/06: ClinicalTrials.gov Identifier: NCT00495287).

Published
2021

16. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne

Author

Pagano, L., Caira, M., Nosari, A., Van Lint, M.T., Candoni, A., Offidani, M., Aloisi, T., Irrera, G., Bonini, A., Picardi, M., Caramatti, C., Invernizzi, R., Mattei, D., Melillo, L., de Waure, C., Reddiconto, G., Fianchi, L., Valentini, C.G., Girmenia, C., Leone, G., and Aversa, F.

Subjects
Mycoses -- Causes of, Mycoses -- Health aspects, Mycoses -- Care and treatment, Mycoses -- Research, Organ transplant recipients -- Health aspects, Organ transplant recipients -- Patient outcomes, Hematopoietic stem cells -- Transplantation, Hematopoietic stem cells -- Methods, Hematopoietic stem cells -- Complications and side effects, Health, Health care industry
Published
2007

17. High throughput molecular characterization of normal karyotype acute myeloid leukemia in the context of the prospective trial 02/06 of the northern italy leukemia group (NILG)

Author

Salmoiraghi, S, Cavagna, R, Zanghì, P, Pavoni, C, Michelato, A, Buklijas, K, Elidi, L, Intermesoli, T, Lussana, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Audisio, E, Terruzzi, E, De Paoli, L, Borlenghi, E, Cavattoni, I, Mattei, D, Scattolin, A, Tajana, M, Ciceri, F, Todisco, E, Campiotti, L, Corradini, P, Fracchiolla, N, Bassan, R, Rambaldi, A, Spinelli, O, Salmoiraghi, Silvia, Cavagna, Roberta, Zanghì, Pamela, Pavoni, Chiara, Michelato, Anna, Buklijas, Ksenija, Elidi, Lara, Intermesoli, Tamara, Lussana, Federico, Oldani, Elena, Caprioli, Chiara, Stefanoni, Paola, Gianfaldoni, Giacomo, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Borlenghi, Erika, Cavattoni, Irene, Mattei, Daniele, Scattolin, Annamaria, Tajana, Monica, Ciceri, Fabio, Todisco, Elisabetta, Campiotti, Leonardo, Corradini, Paolo, Fracchiolla, Nicola, Bassan, Renato, Rambaldi, Alessandro, Spinelli, Orietta, Salmoiraghi, S, Cavagna, R, Zanghì, P, Pavoni, C, Michelato, A, Buklijas, K, Elidi, L, Intermesoli, T, Lussana, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Audisio, E, Terruzzi, E, De Paoli, L, Borlenghi, E, Cavattoni, I, Mattei, D, Scattolin, A, Tajana, M, Ciceri, F, Todisco, E, Campiotti, L, Corradini, P, Fracchiolla, N, Bassan, R, Rambaldi, A, Spinelli, O, Salmoiraghi, Silvia, Cavagna, Roberta, Zanghì, Pamela, Pavoni, Chiara, Michelato, Anna, Buklijas, Ksenija, Elidi, Lara, Intermesoli, Tamara, Lussana, Federico, Oldani, Elena, Caprioli, Chiara, Stefanoni, Paola, Gianfaldoni, Giacomo, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Borlenghi, Erika, Cavattoni, Irene, Mattei, Daniele, Scattolin, Annamaria, Tajana, Monica, Ciceri, Fabio, Todisco, Elisabetta, Campiotti, Leonardo, Corradini, Paolo, Fracchiolla, Nicola, Bassan, Renato, Rambaldi, Alessandro, and Spinelli, Orietta

Abstract

By way of a Next-Generation Sequencing NGS high throughput approach, we defined the mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled into a prospective randomized clinical trial, designed to evaluate an intensified chemotherapy program for remission induction. NPM1, DNMT3A, and FLT3-ITD were the most frequently mutated genes while DNMT3A, FLT3, IDH1, PTPN11, and RAD21 mutations were more common in the NPM1 mutated patients (p < 0.05). IDH1 R132H mutation was strictly associated with NPM1 mutation and mutually exclusive with RUNX1 and ASXL1. In the whole cohort of NK-AML, no matter the induction chemotherapy used, by multivariate analysis, the achievement of complete remission was negatively affected by the SRSF2 mutation. Alterations of FLT3 (FLT3-ITD) and U2AF1 were associated with a worse overall and disease-free survival (p < 0.05). FLT3-ITD positive patients who proceeded to alloHSCT had a survival probability similar to FLT3-ITD negative patients and the transplant outcome was no different when comparing high and low-AR-FLT3-ITD subgroups in terms of both OS and DFS. In conclusion, a comprehensive molecular profile for NK-AML allows for the identification of genetic lesions associated to different clinical outcomes and the selection of the most appropriate and effective treatment strategies, including stem cell transplantation and targeted therapies.

Published
2020

26. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C, Spinelli, O, Salmoiraghi, S, Intermesoli, T, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Elidi, L, Delaini, F, Oldani, E, Gianfaldoni, G, Bosi, A, Marmont, F, Audisio, E, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Falini, B, Pavoni, C, Bassan, R, Rambaldi, A, and Lussana, F

Published
2019

31. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

Author

Spinelli, O, Salmoiraghi, S, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Zannino, L, Intermesoli, T, Lussana, F, Delaini, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Marmont, F, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Audisio, E, Bosi, A, Falini, B, Pavoni, C, Bassan, R, and Rambaldi, A

Published
2018

33. PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C., primary, Spinelli, O., additional, Salmoiraghi, S., additional, Intermesoli, T., additional, Zanghì, P., additional, Cavagna, R., additional, Michelato, A., additional, Buklijas, K., additional, Elidi, L., additional, Delaini, F., additional, Oldani, E., additional, Gianfaldoni, G., additional, Bosi, A., additional, Marmont, F., additional, Audisio, E., additional, Ferrero, D., additional, Terruzzi, E., additional, De Paoli, L., additional, Rossi, G., additional, Borlenghi, E., additional, Cavattoni, I., additional, Tajana, M., additional, Scattolin, A.M., additional, Mattei, D., additional, Corradini, P., additional, Campiotti, L., additional, Ciceri, F., additional, Bernardi, M., additional, Todisco, E., additional, Cortelezzi, A., additional, Cortelazzo, S., additional, Falini, B., additional, Pavoni, C., additional, Bassan, R., additional, Rambaldi, A., additional, and Lussana, F., additional

Published
2019
Full Text
View/download PDF

34. PF259 THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL-INHIBITOR AND LOW-DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY

Author

Loges, S., primary, Heuser, M., additional, Chromik, J., additional, Vigil, C.E., additional, Paschka, P., additional, Re, F., additional, Di Renzo, N., additional, Lemoli, R., additional, Mattei, D., additional, Ben Batalla, I., additional, Hellesøy, M., additional, Micklem, D., additional, Holt, R.J., additional, Schoelermann, J., additional, Lorens, K., additional, Lorens, J.B., additional, Shoaib, M., additional, Aly, H., additional, Brown, A., additional, Fiedler, W.M., additional, Cortes, J.E., additional, and Gjertsen, B.T., additional

Published
2019
Full Text
View/download PDF

35. Digital image correlation from commercial to FOS software : A mature technique for full-field displacement measurements

Author

Belloni, V., Ravanelli, R., Nascetti, Andrea, Di Rita, M., Mattei, D., Crespi, M., Belloni, V., Ravanelli, R., Nascetti, Andrea, Di Rita, M., Mattei, D., and Crespi, M.

Abstract

In the last few decades, there has been a growing interest in studying non-contact methods for full-field displacement and strain measurement. Among such techniques, Digital Image Correlation (DIC) has received particular attention, thanks to its ability to provide these information by comparing digital images of a sample surface before and after deformation. The method is now commonly adopted in the field of civil, mechanical and aerospace engineering and different companies and some research groups implemented 2D and 3D DIC software. In this work a review on DIC software status is given at first. Moreover, a free and open source 2D DIC software is presented, named py2DIC and developed in Python at the Geodesy and Geomatics Division of DICEA of the University of Rome "La Sapienza"; its potentialities were evaluated by processing the images captured during tensile tests performed in the Structural Engineering Lab of the University of Rome "La Sapienza" and comparing them to those obtained using the commercial software Vic-2D developed by Correlated Solutions Inc, USA. The agreement of these results at one hundredth of millimetre level demonstrate the possibility to use this open source software as a valuable 2D DIC tool to measure full-field displacements on the investigated sample surface., QC 20181120r

Published
2018
Full Text
View/download PDF

36. Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment

Author

Mattei, D., Ivanov, A., Ferrai, C., Jordan, P., Guneykaya, D., Buonfiglioli, A., Schaafsma, W., Przanowski, P., Deuther-Conrad, W., Brust, P., Hesse, S., Patt, M., Sabri, O., Ross, T.L., Eggen, B.J.L., Boddeke, E.W.G.M., Kaminska, B., Beule, D., Pombo, A., Kettenmann, H., Wolf, S.A., Molecular Neuroscience and Ageing Research (MOLAR), Translational Immunology Groningen (TRIGR), and Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)

Subjects
IN-VIVO PET, 18 KDA, Minocycline, NEGATIVE SYMPTOMS, Synaptic Transmission, HIPPOCAMPAL NEUROGENESIS, Immune System Phenomena, Mice, DOUBLE-BLIND, Phagocytosis, Alzheimer Disease, Pregnancy, DEFICITS, ANIMAL-MODEL, Animals, Humans, Behavior, Animal, HUMAN BRAIN, Anti-Bacterial Agents, Mice, Inbred C57BL, Disease Models, Animal, EARLY-PHASE SCHIZOPHRENIA, Cardiovascular and Metabolic Diseases, Schizophrenia, Adult Children, Original Article, Female, Microglia, Technology Platforms, TRANSLOCATOR PROTEIN, Function and Dysfunction of the Nervous System, Transcriptome
Abstract

Maternal immune activation (MIA) during pregnancy has been linked to an increased risk of developing psychiatric pathologies in later life. This link may be bridged by a defective microglial phenotype in the offspring induced by MIA, as microglia have key roles in the development and maintenance of neuronal signaling in the central nervous system. The beneficial effects of the immunomodulatory treatment with minocycline on schizophrenic patients are consistent with this hypothesis. Using the MIA mouse model, we found an altered microglial transcriptome and phagocytic function in the adult offspring accompanied by behavioral abnormalities. The changes in microglial phagocytosis on a functional and transcriptional level were similar to those observed in a mouse model of Alzheimer's disease hinting to a related microglial phenotype in neurodegenerative and psychiatric disorders. Minocycline treatment of adult MIA offspring reverted completely the transcriptional, functional and behavioral deficits, highlighting the potential benefits of therapeutic targeting of microglia in psychiatric disorders.

Published
2017

37. NEXT GENERATION SEQUENCING (NGS) CONFIRMED THE ADVERSE CLINICAL IMPACT OF RUNX1 MUTATIONS IN A SUBSET OF ACUTE MYELOID LEUKEMIA NORMAL KARYOTYPE PATIENTS NEGATIVE FOR RISK DEFINING GENES MUTATIONS AND HOMOGENOUSLY TREATED WITHIN A CLINICAL TRIAL (NILG AML 02/06)

Author

Salmoiraghi, S, Zanghi, P, Pavoni, C, Montalvo, Mlg, Ubiali, G, Intermesoli, T, Oldani, E, Marmont, F, Cavattoni, I, Mattei, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Ciceri, F, Campiotti, L, Corradini, P, Cortelezzi, A, Ferrero, D, Audisio, E, Bosi, A, Bassan, R, Rambaldi, A, and Spinelli, O

Published
2017

39. CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE

Author

Bassan, R, Masciulli, A, Intermesoli, T, Spinelli, O, Tosi, M, Pavoni, C, Audisio, E, Cattaneo, C, Fumagalli, M, Cassibba, V, Mattei, D, Romani, C, Cortelezzi, A, Ciceri, F, Scattolin, Am, Vitolo, U, Borlenghi, E, Gallamini, A, Depaoli, L, Campiotti, L, Bocchia, M, Di Bona, E, Oldani, E, and Rambaldi, A

Published
2017

43. Diurnal preference, mood and the response to morning light in relation to polymorphisms in the human clock gene PER3

Author

Turco, M., primary, Biscontin, A., additional, Corrias, M., additional, Caccin, L., additional, Bano, M., additional, Chiaromanni, F., additional, Salamanca, M., additional, Mattei, D., additional, Salvoro, C., additional, Mazzotta, G., additional, De Pittà, C., additional, Middleton, B., additional, Skene, D. J., additional, Montagnese, S., additional, and Costa, R., additional

Published
2017
Full Text
View/download PDF

45. Brain in flames - animal models of psychosis: utility and limitations

Author

Mattei, D., Schweibold, R., and Wolf, S.A.

Subjects
mental disorders, Function and Dysfunction of the Nervous System
Abstract

The neurodevelopmental hypothesis of schizophrenia posits that schizophrenia is a psychopathological condition resulting from aberrations in neurodevelopmental processes caused by a combination of environmental and genetic factors which proceed long before the onset of clinical symptoms. Many studies discuss an immunological component in the onset and progression of schizophrenia. We here review studies utilizing animal models of schizophrenia with manipulations of genetic, pharmacologic, and immunological origin. We focus on the immunological component to bridge the studies in terms of evaluation and treatment options of negative, positive, and cognitive symptoms. Throughout the review we link certain aspects of each model to the situation in human schizophrenic patients. In conclusion we suggest a combination of existing models to better represent the human situation. Moreover, we emphasize that animal models represent defined single or multiple symptoms or hallmarks of a given disease.

Published
2015

46. The SPEED project : SPEEDing up research and development towards high-contrast imaging instruments for the E-ELT

Author

Martinez, P., Preis, O., Gouvret, C., Dejongue, J., Daban, J. -B, Spang, A., Frantz Martinache, Beaulieu, M., Janin-Potiron, P., Abe, L., Fantei-Cujolle, Y., Ottogalli, S., Mattei, D., Carbillet, M., Joseph Louis LAGRANGE (LAGRANGE), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[PHYS.ASTR.IM]Physics [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2015

47. Targetting microglia activation in schizophrenia by minocycline treatment

Author

Mattei, D., Ivanov, A., Ferrai, G., Jordan, P., Guneykaya, D., Schaafsma, W., Przanowski, P., Deuther-Conrad, W., Brust, P., Hesse, S., Eggen, B., Bodekke, E., Kaminska, B., Pombo, A., Kettenmann, H., Wolf, S. A., Mattei, D., Ivanov, A., Ferrai, G., Jordan, P., Guneykaya, D., Schaafsma, W., Przanowski, P., Deuther-Conrad, W., Brust, P., Hesse, S., Eggen, B., Bodekke, E., Kaminska, B., Pombo, A., Kettenmann, H., and Wolf, S. A.

Abstract

The importance of the brain's phagocyte – the microglia – came recently into focus as a novel therapeutic target in psychiatric disorders. Dysregulations of microglia have been reported in post mortem tissue and also in vivo by increased radio ligand binding to the (phagocyte-specific) TSPO receptor in brains of schizophrenic patients. The tetracycline minocycline that partially acts on microglia has been shown to improve mainly negative symptoms in a few clinical studies. We here use an animal model of maternal immune activation to test its validity for clinical translation and investigate the pathways that are targeted by minocycline specific in microglia. Pregnant dams were injected intraperitoneally with the viral mimic PolyI:C or saline at gestational day 15 and the offspring was tested for behavioral deficits at postnatal day 60. Indeed, the offspring showed behavioral correlates of schizophrenia like decreased pre-pulse inhibition, sociability and cognitive performance along with an increased binding potential to the TSPO shown by autoradiography using [18F]GE-180 on hippocampal slices. This was accompanied by a profoundly altered transcriptome signature in hippocampal microglia and decreased phagocytic activity. Thereafter, mice were treated for five weeks with minocycline (3 mg/kg/day). This treatment normalized the behavioral deficits, TSPO binding and phagocytic activity and restored the transcriptome signature towards control levels. Our findings indicate that minocycline is a potent drug to affect specific microglial functions and thereby attenuate symptoms of schizophrenia in an animal model.

Published
2016

48. TWO-STEP RESPONSE-ORIENTED INDUCTION PREDICTS LONG-TERM OUTCOME OF ADULT PATIENTS WITH STANDARD- AND HIGH-RISK ACUTE MYELOID LEUKAEMIA (AML): A NORTHERN ITALY LEUKAEMIA GROUP (NILG) STUDY

Author

Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

49. IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG)

Author

Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

50. Improved Clinical Outcome of Adult Patients with Ph plus ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group

Author

Rambaldi A, Spinelli O, Oldani E, Grassi A, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi Deliliers G, Mannelli F, Levis A, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Tosi M, Bussini A, Intermesoli T, Bassan R., CICERI , FABIO, Rambaldi, A, Spinelli, O, Oldani, E, Grassi, A, Rossi, G, Pogliani, Em, Di Bona, E, Angelucci, E, Cavattoni, I, Lambertenghi Deliliers, G, Mannelli, F, Levis, A, Ciceri, Fabio, Mattei, D, Borlenghi, E, Terruzzi, E, Borghero, C, Romani, C, Tosi, M, Bussini, A, Intermesoli, T, and Bassan, R.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results